Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN5069 for Pain Due to Osteoarthritis of the Knee
2018-004730-15Phase 2Terminated
- Sponsor
- Regeneron Pharmaceuticals
- Start
- May 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in knee osteoarthritis (OA) and osteoarthritis (OA) comparing REGN5069 with Placebo (2 arms). Primary endpoint: Change in WOMAC pain subscale score. Started May 2019; status: terminated.
02
Drugs
Nadecnemab
03
Conditions
knee osteoarthritis (OA)osteoarthritis (OA)
Beyond the preview
Go deeper on 2018-004730-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004730-15.